The investigational antibody promotes the activation of both natural killer cells and T cells, with the potential to elicit a strong anti-tumor response and promote immunological memory, according to a statement.
Surface Oncology will receive a $30 million milestone payment at the start of the first phase 1 study for GSK4381562. The company is also eligible to receive an additional $700 million in future milestone payments, as well as tiered royalties on global net sales.
Price: 5.89, Change: +0.12, Percent Change: +0.02
|MiMedx Says Glass Lewis Recommends in Favor of Direc...|
|T2 Biosystems Says It Secured US Patent Covering Met...|
|TherapeuticsMD Gets FDA Approval for Supplemental Ne...|
|Deere Raises Fiscal 2022 Profit Outlook After Postin...|
|Covetrus Says it Gets Proposal From Clayton, Dubilie...|